:ID,name,:LABEL,understanding_criteria,schema_version,description,author,creation_date,last_updated,total_concepts:int,level,prerequisites
wgv_001,Wegovy,Curriculum,,1.0.0,Confidently discuss Wegovy with doctors,,2026-02-19,2026-02-19,5,,
WGV_001,Mechanism of Action and Clinical Evidence Foundation,Concept,"Explain that semaglutide is a human glucagon-like peptide-1 or GLP-1 analogue produced by recombinant DNA technology;Describe that GLP-1 receptor agonists work by increasing insulin secretion, decreasing glucagon secretion, and slowing gastric emptying;Identify that delayed gastric emptying contributes to reduced appetite and caloric intake supporting weight management;State that Wegovy demonstrated significant weight loss in pivotal trials as adjunct to reduced-energy diet and increased physical activity;Explain that the cardiovascular outcomes trial showed reduction in major adverse cardiovascular events including cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke in adults with established cardiovascular disease;Recognize that clinical benefits require adherence to lifestyle modifications including reduced-calorie diet and increased physical activity;Describe that weight loss typically occurs gradually over the dose escalation period with continued effect at maintenance dose",1.0.0,Understanding mechanism of action and clinical evidence foundation: Explain that semaglutide is a human glucagon-like peptide-1 or GLP-1 analogue produced by recombinant DNA technology,,2026-02-19,2026-02-19,,Foundational,
WGV_002,Approved Indications and Patient Selection Criteria,Concept,"Identify that Wegovy is indicated for chronic weight management in adults with BMI of 30 kg/m2 or greater representing obesity;Explain that Wegovy is also indicated for adults with BMI of 27 kg/m2 to less than 30 kg/m2 representing overweight in the presence of at least one weight-related comorbidity;State that adolescent indication applies to patients aged 12 years and above with obesity defined as BMI at or above 95th percentile per CDC growth charts and body weight above 60 kg;Describe that treatment must be re-evaluated and discontinued in adolescents if BMI has not reduced by at least 5 percent after 12 weeks on the 2.4 mg or maximum tolerated dose;Identify the cardiovascular risk reduction indication for adults with established cardiovascular disease, BMI of 27 kg/m2 or greater, and without established Type 1 or Type 2 diabetes;Explain that Wegovy is indicated as adjunct to standard of care therapy for reducing risk of major adverse cardiovascular events;Recognize that Wegovy must be used as adjunct to reduced-energy diet and increased physical activity in all indications;State that it is recommended to regularly review treatment goals in adolescents particularly once target weight such as BMI less than 85th percentile has been achieved",1.0.0,Understanding approved indications and patient selection criteria: Identify that Wegovy is indicated for chronic weight management in adults with BMI of 30 kg/m2 or greater representing obesity,,2026-02-19,2026-02-19,,Foundational,
WGV_003,"Dosing Protocol, Administration Technique, and Device Handling",Concept,"Identify the maintenance dose of Wegovy as 2.4 mg once weekly administered subcutaneously;Explain the 16-week dose escalation schedule starting at 0.25 mg weekly for weeks 1 through 4, then 0.5 mg for weeks 5 through 8, then 1 mg for weeks 9 through 12, then 1.7 mg for weeks 13 through 16, before reaching maintenance dose of 2.4 mg;Describe that dose escalation is designed to reduce the likelihood of gastrointestinal symptoms;State that if significant gastrointestinal symptoms occur, delaying dose escalation should be considered until symptoms improve;Explain that if patients do not tolerate the 2.4 mg dose, it can be decreased to 1.7 mg weekly for maintenance with re-escalation to 2.4 mg attempted if tolerated;Identify that weekly doses higher than 2.4 mg are not recommended;State that Wegovy can be administered at any time of day with or without meals;Describe the three approved injection sites as abdomen, thigh, or upper arm with ability to change sites without dose adjustment;Explain that Wegovy should be injected subcutaneously only and not administered intravenously or intramuscularly;State the missed dose protocol as administer within 5 days if missed, but skip if more than 5 days have passed and resume regular schedule;Describe that the day of weekly administration can be changed if necessary as long as the time between two doses is at least 3 days or 72 hours;Identify that if multiple doses are missed, reducing the starting dose for re-initiation should be considered;Explain that the single-dose pen is for single use in one patient only and should be discarded after use with injection taking about 5 to 10 seconds;Describe that the FlexTouch pen contains 4 doses and is for use by one patient only with a new needle attached for each use and needle discarded after each use;State that Wegovy should be stored in refrigerator at 2 to 8 degrees Celsius and protected from light;Recognize that patients should read the instruction for use included in the package leaflet carefully before administering Wegovy",1.0.0,"Understanding dosing protocol, administration technique, and device handling: Identify the maintenance dose of Wegovy as 2.4 mg once weekly administered subcutaneously",,2026-02-19,2026-02-19,,Intermediate,
WGV_004,"Contraindications, Boxed Warnings, and Critical Safety Precautions",Concept,"Identify that Wegovy is contraindicated in patients with hypersensitivity to semaglutide or any excipients;Explain that Wegovy is contraindicated in patients with personal or family history of medullary thyroid carcinoma or MTC;State that Wegovy is contraindicated in patients with Multiple Endocrine Neoplasia syndrome type 2 or MEN 2;Describe that patients should be counseled on the risk of thyroid C-cell tumors and symptoms of thyroid tumors including neck mass, hoarseness, dysphagia, or dyspnea;Recognize that acute pancreatitis including fatal and non-fatal hemorrhagic or necrotizing pancreatitis has been observed with GLP-1 receptor agonists including semaglutide;Explain that patients should be informed of characteristic symptoms of acute pancreatitis including persistent severe abdominal pain;State that if pancreatitis is suspected, Wegovy should be discontinued, and if confirmed, Wegovy should not be restarted;Identify that caution should be exercised in patients with a history of pancreatitis;Describe that cases of pulmonary aspiration have been reported in patients receiving GLP-1 receptor agonists undergoing general anesthesia or deep sedation;Explain that delayed gastric emptying with semaglutide increases risk of residual gastric content prior to procedures with general anesthesia or deep sedation;State that increased risk of aspiration should be considered prior to performing procedures with general anesthesia or deep sedation despite adherence to preoperative fasting recommendations;Recognize that cholelithiasis and cholecystitis or gallbladder disease have been reported with GLP-1 receptor agonists;Identify that patients should be informed of symptoms of gallbladder disease including upper abdominal pain, fever, jaundice, and clay-colored stools;Explain that anaphylaxis and angioedema have been reported with GLP-1 receptor agonists including semaglutide;State that if hypersensitivity reactions occur, patients should discontinue Wegovy and promptly seek medical advice",1.0.0,"Understanding contraindications, boxed warnings, and critical safety precautions: Identify that Wegovy is contraindicated in patients with hypersensitivity to semaglutide or any excipients",,2026-02-19,2026-02-19,,Advanced,
WGV_005,"Special Populations, Drug Interactions, and Gastrointestinal Safety Management",Concept,"State that Wegovy is not recommended during pregnancy and should be discontinued at least 2 months before a planned pregnancy due to long half-life;Explain that it is unknown whether semaglutide is excreted in human milk and benefits of breastfeeding should be considered along with potential adverse effects on the infant;Identify that Wegovy must not be used as a substitute for insulin in patients with diabetes;Describe that Wegovy should not be used in combination with other GLP-1 receptor agonist products;Explain that when initiating Wegovy, reducing the dose of concomitantly administered insulin or insulin secretagogues such as sulfonylureas should be considered to reduce hypoglycemia risk;Recognize that patients treated with Wegovy in combination with sulfonylurea or insulin may have increased risk of hypoglycemia;State that rapid improvement in glucose control has been associated with temporary worsening of diabetic retinopathy and patients with history of diabetic retinopathy should be monitored;Identify that Wegovy is not recommended in patients with type 2 diabetes with uncontrolled or potentially unstable diabetic retinopathy;Describe that delayed gastric emptying may impact absorption of concomitantly administered oral medications and caution should be applied with medications that have narrow therapeutic index;Explain that nausea, vomiting, diarrhea, and constipation are common gastrointestinal adverse reactions that may cause dehydration;State that dehydration associated with gastrointestinal adverse reactions could deteriorate renal function in patients with impaired renal function;Recognize that postmarketing reports include acute kidney injury and worsening of chronic renal failure requiring hemodialysis in some cases in patients treated with semaglutide;Identify that no dose adjustment is required for patients with renal impairment but experience in patients with severe renal impairment with CrCL less than 30 mL per min is limited;Explain that semaglutide is not recommended for use in patients with end-stage renal disease;State that no dose adjustment is required for patients with hepatic impairment but experience in patients with severe hepatic impairment is limited and caution should be exercised;Describe that no dose adjustment is required based on age but therapeutic experience in patients 85 years of age and older is limited;Recognize that Wegovy is subject to additional monitoring in Australia allowing quick identification of new safety information;Explain that healthcare professionals should report any suspected adverse events to the TGA at www.tga.gov.au/reporting-problems",1.0.0,"Understanding special populations, drug interactions, and gastrointestinal safety management: State that Wegovy is not recommended during pregnancy and should be discontinued at least 2 months before a planned pregnancy due to long half-life",,2026-02-19,2026-02-19,,Advanced,
